Roche’s anti-TIGIT drug tiragolumab has failed a lung cancer study, denting enthusiasm for the programme just as there were signs that it was getting back on track after a series of disappointing trial results.The new data comes from the phase 2/3 SKYSCRAPER-06 study, which evaluated tiragolumab in combination with Roche’s PD-L1 inhibitor Tecentriq (atezolizumab) and chemotherapy as a first-line treatment for locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC).
